We conducted a PD-L1 humanized syngeneic murine tumor allograft study to verify the antagonist effect of pentamidine against human PD-L1 in vivo. The results indicated that pentamidine decreased the volume of allograft tumors and extended the survival of tumor-bearing mice without exhibiting liver or spleen toxicity. The gene discussed is CD274; the disease is neoplasm.